{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:33:07Z","timestamp":1777480387291,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T00:00:00Z","timestamp":1588377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T00:00:00Z","timestamp":1588377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s00198-020-05430-z","type":"journal-article","created":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T22:02:15Z","timestamp":1588456935000},"page":"1741-1747","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Once-yearly zoledronic acid and change in abdominal aortic calcification over 3\u00a0years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6481-704X","authenticated-orcid":false,"given":"G.","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. I.","family":"Keen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. V.","family":"Host","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. L.","family":"Laslett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Winzenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. E.","family":"Wluka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,2]]},"reference":[{"key":"5430_CR1","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u20131809","journal-title":"N Engl J Med"},{"key":"5430_CR2","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","volume":"379","author":"IR Reid","year":"2018","unstructured":"Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD (2018) Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med 379:2407\u20132416","journal-title":"N Engl J Med"},{"key":"5430_CR3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1359\/jbmr.090704","volume":"25","author":"CS Colon-Emeric","year":"2010","unstructured":"Colon-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91\u201397","journal-title":"J Bone Miner Res"},{"key":"5430_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/jbmr.3860","volume":"35","author":"IR Reid","year":"2019","unstructured":"Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Bastin S, Gamble GD (2019) Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women. J Bone Miner Res 35:20\u201327. https:\/\/doi.org\/10.1002\/jbmr.3860","journal-title":"J Bone Miner Res"},{"key":"5430_CR5","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/joim.12087","volume":"274","author":"EL Grove","year":"2013","unstructured":"Grove EL, Abrahamsen B, Vestergaard P (2013) Heart failure in patients treated with bisphosphonates. J Intern Med 274:342\u2013350","journal-title":"J Intern Med"},{"key":"5430_CR6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00198-012-2213-5","volume":"24","author":"JH Kang","year":"2013","unstructured":"Kang JH, Keller JJ, Lin HC (2013) Bisphosphonates reduced the risk of acute myocardial infarction: a 2-year follow-up study. Osteoporos Int 24:271\u2013277","journal-title":"Osteoporos Int"},{"key":"5430_CR7","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/jbmr.1792","volume":"28","author":"F Wolfe","year":"2013","unstructured":"Wolfe F, Bolster MB, O'Connor CM, Michaud K, Lyles KW, Colon-Emeric CS (2013) Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. J Bone Miner Res 28:984\u2013991","journal-title":"J Bone Miner Res"},{"key":"5430_CR8","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1161\/CIRCULATIONAHA.107.743161","volume":"117","author":"LL Demer","year":"2008","unstructured":"Demer LL, Tintut Y (2008) Vascular calcification: pathobiology of a multifaceted disease. Circulation 117:2938\u20132948","journal-title":"Circulation"},{"key":"5430_CR9","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1359\/jbmr.080504","volume":"23","author":"JT Chow","year":"2008","unstructured":"Chow JT, Khosla S, Melton LJ 3rd, Atkinson EJ, Camp JJ, Kearns AE (2008) Abdominal aortic calcification, BMD, and bone microstructure: a population-based study. J Bone Miner Res 23:1601\u20131612","journal-title":"J Bone Miner Res"},{"key":"5430_CR10","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1210\/jc.2003-030964","volume":"89","author":"E Schulz","year":"2004","unstructured":"Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V (2004) Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89:4246\u20134253","journal-title":"J Clin Endocrinol Metab"},{"key":"5430_CR11","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1161\/01.ATV.20.8.1926","volume":"20","author":"AE Hak","year":"2000","unstructured":"Hak AE, Pols Huibert AP, van Hemert AM, Hofman A, Witteman Jacqueline CM (2000) Progression of aortic calcification is associated with metacarpal bone loss during menopause. Arterioscler Thromb Vasc Biol 20:1926\u20131931","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5430_CR12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/BF02390833","volume":"68","author":"D Kiel","year":"2001","unstructured":"Kiel D, Kauppila L, Cupples L, Hannan M, O'donnell C, Wilson P (2001) Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham heart study. Calcif Tissue Int 68:271\u2013276","journal-title":"Calcif Tissue Int"},{"key":"5430_CR13","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1210\/jc.2004-1324","volume":"89","author":"MR Rubin","year":"2004","unstructured":"Rubin MR, Silverberg SJ (2004) Vascular calcification and osteoporosis\u2014the nature of the nexus. J Clin Endocrinol Metab 89:4243\u20134245","journal-title":"J Clin Endocrinol Metab"},{"key":"5430_CR14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/ki.2008.646","volume":"75","author":"KA Lomashvili","year":"2009","unstructured":"Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O'Neill WC (2009) Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 75:617\u2013625","journal-title":"Kidney Int"},{"key":"5430_CR15","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/sj.ki.5001841","volume":"70","author":"PA Price","year":"2006","unstructured":"Price PA, Roublick AM, Williamson MK (2006) Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 70:1577\u20131583","journal-title":"Kidney Int"},{"key":"5430_CR16","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1093\/jn\/131.11.2910","volume":"131","author":"PA Price","year":"2001","unstructured":"Price PA, Buckley JR, Williamson MK (2001) The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr 131:2910\u20132915","journal-title":"J Nutr"},{"key":"5430_CR17","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.ATV.21.5.817","volume":"21","author":"PA Price","year":"2001","unstructured":"Price PA, Faus SA, Williamson MK (2001) Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 21:817\u2013824","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5430_CR18","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/sj.ki.5001899","volume":"70","author":"V Persy","year":"2006","unstructured":"Persy V, De Broe M, Ketteler M (2006) Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney Int 70:1537\u20131538","journal-title":"Kidney Int"},{"key":"5430_CR19","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2362.1970.tb00591.x","volume":"1","author":"HA Fleisch","year":"1970","unstructured":"Fleisch HA, Russell RG, Bisaz S, Muhlbauer RC, Williams DA (1970) The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Investig 1:12\u201318","journal-title":"Eur J Clin Investig"},{"key":"5430_CR20","doi-asserted-by":"crossref","first-page":"RA1","DOI":"10.12659\/MSM.882181","volume":"18","author":"W Karwowski","year":"2012","unstructured":"Karwowski W, Naumnik B, Szczepanski M, Mysliwiec M (2012) The mechanism of vascular calcification - a systematic review. Med Sci Monit 18:RA1\u2013R11","journal-title":"Med Sci Monit"},{"key":"5430_CR21","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1681\/ASN.V12112511","volume":"12","author":"M Cozzolino","year":"2001","unstructured":"Cozzolino M, Dusso AS, Slatopolsky E (2001) Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 12:2511\u20132516","journal-title":"J Am Soc Nephrol"},{"key":"5430_CR22","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1161\/01.CIR.100.21.2168","volume":"100","author":"CM Shanahan","year":"1999","unstructured":"Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME (1999) Medial localization of mineralization-regulating proteins in association with Monckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation 100:2168\u20132176","journal-title":"Circulation"},{"key":"5430_CR23","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2008.10.043","volume":"602","author":"L Wu","year":"2009","unstructured":"Wu L, Zhu L, Shi WH, Zhang J, Ma D, Yu B (2009) Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. Eur J Pharmacol 602:124\u2013131","journal-title":"Eur J Pharmacol"},{"key":"5430_CR24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00044011-200626040-00006","volume":"26","author":"T Ariyoshi","year":"2006","unstructured":"Ariyoshi T, Eishi K, Sakamoto I, Matsukuma S, Odate T (2006) Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig 26:215\u2013222","journal-title":"Clin Drug Investig"},{"key":"5430_CR25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1744-9987.2006.00345.x","volume":"10","author":"H Hashiba","year":"2006","unstructured":"Hashiba H, Aizawa S, Tamura K, Kogo H (2006) Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. Ther Apher Dial 10:59\u201364","journal-title":"Ther Apher Dial"},{"key":"5430_CR26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1526-0968.2004.00136.x","volume":"8","author":"H Hashiba","year":"2004","unstructured":"Hashiba H, Aizawa S, Tamura K, Shigematsu T, Kogo H (2004) Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Ther Apher Dial 8:241\u2013247","journal-title":"Ther Apher Dial"},{"key":"5430_CR27","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0272-6386(04)00937-0","volume":"44","author":"K Nitta","year":"2004","unstructured":"Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, Aoki T, Nihei H (2004) Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kidney Dis 44:680\u2013688","journal-title":"Am J Kidney Dis"},{"key":"5430_CR28","first-page":"269613","volume":"2014","author":"M Okamoto","year":"2014","unstructured":"Okamoto M, Yamanaka S, Yoshimoto W, Shigematsu T (2014) Alendronate as an effective treatment for bone loss and vascular calcification in kidney transplant recipients. J Transp Secur 2014:269613","journal-title":"J Transp Secur"},{"key":"5430_CR29","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1097\/TP.0b013e3181dc13d0","volume":"89","author":"JV Torregrosa","year":"2010","unstructured":"Torregrosa JV, Fuster D, Gentil MA, Marcen R, Guirado L, Zarraga S, Bravo J, Burgos D, Monegal A, Mux\u00ed A, Garc\u00eda S (2010) Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients. Transplantation 89:1476\u20131481","journal-title":"Transplantation"},{"key":"5430_CR30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.ajkd.2009.12.039","volume":"56","author":"ND Toussaint","year":"2010","unstructured":"Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG (2010) Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 56:57\u201368","journal-title":"Am J Kidney Dis"},{"key":"5430_CR31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s00198-004-1662-x","volume":"16","author":"LB Tanko","year":"2005","unstructured":"Tanko LB, Qin G, Alexandersen P, Bagger YZ, Christiansen C (2005) Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 16:184\u2013190","journal-title":"Osteoporos Int"},{"key":"5430_CR32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12265-018-9802-4","volume":"11","author":"A Synetos","year":"2018","unstructured":"Synetos A, Toutouzas K, Drakopoulou M, Koutagiar I, Benetos G, Kotronias R, Anousakis-Vlachochristou N, Latsios G, Karanasos A, Agrogiannis G, Metaxas M, Stathogiannis K, Papanikolaou A, Georgakopoulos A, Pianou N, Tsiamis E, Patsouris E, Papalois A, Cokkinos D, Anagnostopoulos C, Tousoulis D (2018) Inhibition of aortic valve calcification by local delivery of zoledronic acid-an experimental study. J Cardiovasc Transl Res 11:192\u2013200","journal-title":"J Cardiovasc Transl Res"},{"key":"5430_CR33","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822","journal-title":"N Engl J Med"},{"key":"5430_CR34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000715","volume":"2","author":"JT Schousboe","year":"2007","unstructured":"Schousboe JT, Wilson KE, Hangartner TN (2007) Detection of aortic calcification during vertebral fracture assessment (VFA) compared to digital radiography. PLoS One 2:e715","journal-title":"PLoS One"},{"key":"5430_CR35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1359\/jbmr.091005","volume":"25","author":"MJ Bolland","year":"2010","unstructured":"Bolland MJ, Wang TK, van Pelt NC, Horne AM, Mason BH, Ames RW, Grey AB, Ruygrok PN, Gamble GD, Reid IR (2010) Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. J Bone Miner Res 25:505\u2013512","journal-title":"J Bone Miner Res"},{"key":"5430_CR36","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RG Russell","year":"2008","unstructured":"Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733\u2013759","journal-title":"Osteoporos Int"},{"key":"5430_CR37","first-page":"85","volume":"27","author":"P Mansueto","year":"2011","unstructured":"Mansueto P, Vitale G, Seidita A, Guarneri F, Pepe I, Rinollo C, Di Rosa S, Rini G, Cillari E, Di Fede G (2011) Mevalonate pathway: role of bisphosphonates and statins. Acta Medica Mediterranea 27:85\u201395","journal-title":"Acta Medica Mediterranea"},{"key":"5430_CR38","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.biocel.2010.09.010","volume":"42","author":"Y Ye","year":"2010","unstructured":"Ye Y, Mou Y, Bai B, Li L, Chen GP, Hu SJ (2010) Knockdown of farnesylpyrophosphate synthase prevents angiotensin II-mediated cardiac hypertrophy. Int J Biochem Cell Biol 42:2056\u20132064","journal-title":"Int J Biochem Cell Biol"},{"key":"5430_CR39","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1097\/HJH.0b013e328330b845","volume":"27","author":"M Bombelli","year":"2009","unstructured":"Bombelli M, Facchetti R, Carugo S, Madotto F, Arenare F, Quarti-Trevano F, Capra A, Giannattasio C, Dell\u02bcOro R, Grassi G, Sega R, Mancia G (2009) Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens 27:2458\u20132464","journal-title":"J Hypertens"},{"key":"5430_CR40","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1517\/14728222.11.7.941","volume":"11","author":"S Galluzzo","year":"2007","unstructured":"Galluzzo S, Santini D, Vincenzi B, Caccamo N, Meraviglia F, Salerno A, Dieli F, Tonini G (2007) Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity. Expert Opin Ther Targets 11:941\u2013954","journal-title":"Expert Opin Ther Targets"},{"key":"5430_CR41","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1161\/CIRCRESAHA.117.310954","volume":"120","author":"T Hamid","year":"2017","unstructured":"Hamid T, Prabhu SD (2017) Immunomodulation is the key to cardiac repair. Circ Res 120:1530\u20131532","journal-title":"Circ Res"},{"key":"5430_CR42","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","volume":"17","author":"T Tanvetyanon","year":"2006","unstructured":"Tanvetyanon T, Stiff PJ (2006) Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17:897\u2013907","journal-title":"Ann Oncol"},{"key":"5430_CR43","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1161\/CIRCRESAHA.110.234914","volume":"109","author":"CM Shanahan","year":"2011","unstructured":"Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM (2011) Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 109:697\u2013711","journal-title":"Circ Res"},{"key":"5430_CR44","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/sj.ki.5002241","volume":"71","author":"KR Neves","year":"2007","unstructured":"Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Neves CL, Magalhaes AO, Custodio MR, Batista DG, Jorgetti V, Moyses RM (2007) Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 71:1262\u20131270","journal-title":"Kidney Int"},{"key":"5430_CR45","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/pmj.76.897.418","volume":"76","author":"M Pirmohamed","year":"2000","unstructured":"Pirmohamed M (2000) Commentary\u2014bisphosphonates and calcium homoeostasis. Postgrad Med J 76:418\u2013419","journal-title":"Postgrad Med J"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05430-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-020-05430-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-020-05430-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T16:15:11Z","timestamp":1620058511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-020-05430-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,2]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["5430"],"URL":"https:\/\/doi.org\/10.1007\/s00198-020-05430-z","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,2]]},"assertion":[{"value":"22 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DA is a recipient of a NHMRC\/MRFF Career Development Fellowship (Level 1). LLL is a recipient of an NHMRC Early Career Fellowship. AEW is a recipient of a NHMRC TRIP Fellowship. GJ is a recipient of a NHMRC Practitioner Fellowship. GC, HK, LVH, DA, LLL, TW, AEW, DMB, and GJ declare that they have no other conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}